KR101257233B1 - 세로토닌 수용체 조절제로서의 트리사이클릭 인데노-피롤유도체 - Google Patents

세로토닌 수용체 조절제로서의 트리사이클릭 인데노-피롤유도체 Download PDF

Info

Publication number
KR101257233B1
KR101257233B1 KR1020077002230A KR20077002230A KR101257233B1 KR 101257233 B1 KR101257233 B1 KR 101257233B1 KR 1020077002230 A KR1020077002230 A KR 1020077002230A KR 20077002230 A KR20077002230 A KR 20077002230A KR 101257233 B1 KR101257233 B1 KR 101257233B1
Authority
KR
South Korea
Prior art keywords
methyl
pyrrole
mmol
hexahydroindeno
calcd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020077002230A
Other languages
English (en)
Korean (ko)
Other versions
KR20080025657A (ko
Inventor
유세프 엘 베나니
베어드 허크
마이클 제이 로바지
Original Assignee
아더시스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아더시스 인코포레이티드 filed Critical 아더시스 인코포레이티드
Publication of KR20080025657A publication Critical patent/KR20080025657A/ko
Application granted granted Critical
Publication of KR101257233B1 publication Critical patent/KR101257233B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/90—Benzo [c, d] indoles; Hydrogenated benzo [c, d] indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/70—[b]- or [c]-condensed containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020077002230A 2004-07-29 2005-07-26 세로토닌 수용체 조절제로서의 트리사이클릭 인데노-피롤유도체 Expired - Fee Related KR101257233B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US59204704P 2004-07-29 2004-07-29
US60/592,047 2004-07-29
PCT/US2005/026415 WO2007081299A2 (en) 2004-07-29 2005-07-26 Tricyclic indeno-pyrrole derivatives as serotonin receptor modulators

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020137007788A Division KR20130047765A (ko) 2004-07-29 2005-07-26 세로토닌 수용체 조절제로서의 트리사이클릭 인데노-피롤 유도체

Publications (2)

Publication Number Publication Date
KR20080025657A KR20080025657A (ko) 2008-03-21
KR101257233B1 true KR101257233B1 (ko) 2013-04-29

Family

ID=37075566

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020137007788A Withdrawn KR20130047765A (ko) 2004-07-29 2005-07-26 세로토닌 수용체 조절제로서의 트리사이클릭 인데노-피롤 유도체
KR1020077002230A Expired - Fee Related KR101257233B1 (ko) 2004-07-29 2005-07-26 세로토닌 수용체 조절제로서의 트리사이클릭 인데노-피롤유도체

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1020137007788A Withdrawn KR20130047765A (ko) 2004-07-29 2005-07-26 세로토닌 수용체 조절제로서의 트리사이클릭 인데노-피롤 유도체

Country Status (16)

Country Link
US (5) US20060025601A1 (enExample)
EP (1) EP1841738A4 (enExample)
JP (1) JP4990164B2 (enExample)
KR (2) KR20130047765A (enExample)
CN (1) CN101516372A (enExample)
AR (1) AR050274A1 (enExample)
AU (1) AU2005333518B2 (enExample)
BR (1) BRPI0512869A (enExample)
CA (1) CA2603249C (enExample)
IL (1) IL180977A (enExample)
NO (1) NO20071102L (enExample)
NZ (1) NZ552806A (enExample)
RU (1) RU2007107494A (enExample)
TW (1) TWI377195B (enExample)
WO (1) WO2007081299A2 (enExample)
ZA (1) ZA200700684B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4990164B2 (ja) * 2004-07-29 2012-08-01 アサーシス， インク． セロトニン受容体モジュレーターとしての三環系インデノ−ピロール誘導体
EP2727585A1 (en) 2006-05-16 2014-05-07 Takeda Pharmaceutical Company Limited In-vivo screening method
EP1988091B1 (en) 2007-02-07 2015-06-10 Kyowa Hakko Kirin Co., Ltd. Tricyclic compounds
US20100266504A1 (en) 2007-11-15 2010-10-21 Takahiro Matsumoto Condensed pyridine derivative and use thereof
WO2009097995A1 (de) * 2008-02-07 2009-08-13 Sanofi-Aventis Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
JP5559689B2 (ja) 2008-08-06 2014-07-23 協和発酵キリン株式会社 ３環系化合物
TW201041851A (en) 2009-03-10 2010-12-01 Organon Nv Tricyclic heterocyclic derivatives
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120053A1 (de) 2011-03-08 2012-09-13 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
CN106380440B (zh) * 2016-08-30 2019-02-01 华东师范大学 一种茚酮并吡咯类衍生物及其合成方法和应用
CN106631989B (zh) * 2016-11-26 2019-07-16 威海迪素制药有限公司 一种盐酸多奈哌齐有关物质e的制备方法
US20210052600A1 (en) 2017-12-27 2021-02-25 Takeda Pharmaceutical Company Limited Therapeutic agents for stress urinary incontinence and incotinence of feces

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5244888A (en) 1989-11-17 1993-09-14 Abbott Laboratories 5-HT selective agents
US5646173A (en) 1993-10-22 1997-07-08 Hoffmann-La Roche Inc. Tricyclic pyrrole derivatives useful as 5-HT selective agents

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0170093B1 (en) * 1984-07-25 1990-03-07 Abbott Laboratories 1,2,3,3a,8,8a-hexahydro-indeno-(1,2-c)pyrrdes
US4622405A (en) * 1984-07-25 1986-11-11 Abbott Laboratories 1,2,3,3a,8,8a-hexahydro-indeno[1,2-c]pyrroles useful in the treatment of hypertension
US5049564A (en) * 1989-11-17 1991-09-17 Abbott Laboratories 5-HT selective agents
ATE139230T1 (de) * 1988-12-15 1996-06-15 Abbott Lab 5-ht-selektive mittel
US7351711B2 (en) * 2003-07-31 2008-04-01 Janssen Pharmaceutical, N.V. Tricyclic indanyls as integrin inhibitors
TWI350168B (en) * 2004-05-07 2011-10-11 Incyte Corp Amido compounds and their use as pharmaceuticals
JP4990164B2 (ja) * 2004-07-29 2012-08-01 アサーシス， インク． セロトニン受容体モジュレーターとしての三環系インデノ−ピロール誘導体

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5244888A (en) 1989-11-17 1993-09-14 Abbott Laboratories 5-HT selective agents
US5646173A (en) 1993-10-22 1997-07-08 Hoffmann-La Roche Inc. Tricyclic pyrrole derivatives useful as 5-HT selective agents

Also Published As

Publication number Publication date
CA2603249C (en) 2014-01-21
TWI377195B (en) 2012-11-21
US20140206739A1 (en) 2014-07-24
IL180977A (en) 2012-08-30
AU2005333518A1 (en) 2007-02-22
AU2005333518A8 (en) 2008-08-07
CA2603249A1 (en) 2007-07-19
BRPI0512869A (pt) 2008-04-08
ZA200700684B (en) 2008-10-29
US9096520B2 (en) 2015-08-04
US20060025601A1 (en) 2006-02-02
US7935830B2 (en) 2011-05-03
JP4990164B2 (ja) 2012-08-01
US20120252859A1 (en) 2012-10-04
KR20080025657A (ko) 2008-03-21
IL180977A0 (en) 2009-02-11
NZ552806A (en) 2009-09-25
AU2005333518B2 (en) 2010-12-02
NO20071102L (no) 2007-04-20
WO2007081299A3 (en) 2007-09-20
AR050274A1 (es) 2006-10-11
JP2008508365A (ja) 2008-03-21
US20110172283A1 (en) 2011-07-14
RU2007107494A (ru) 2008-09-10
TW200619196A (en) 2006-06-16
US20090239925A1 (en) 2009-09-24
US8716324B2 (en) 2014-05-06
CN101516372A (zh) 2009-08-26
EP1841738A2 (en) 2007-10-10
US8232311B2 (en) 2012-07-31
EP1841738A4 (en) 2010-06-02
KR20130047765A (ko) 2013-05-08
WO2007081299A2 (en) 2007-07-19

Similar Documents

Publication Publication Date Title
US7935830B2 (en) Tricyclic indeno-pyrrole derivatives as serotonin receptor modulators
US7981919B2 (en) Tricyclic heteroaryl piperazines, pyrrolidines and azetidines as serotonin receptor modulators
JP5188986B2 (ja) セロトニン５−ｈｔ２ｃ受容体のリガンドとしてのチオフェニルおよびピロリルアゼピンならびにこの使用
KR101216984B1 (ko) 세로토닌 수용체 조절자로서의 치환된 아제핀 유도체

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P18-X000 Priority claim added or amended

St.27 status event code: A-2-2-P10-P18-nap-X000

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

J201 Request for trial against refusal decision
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201

A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PB0901 Examination by re-examination before a trial

St.27 status event code: A-6-3-E10-E12-rex-PB0901

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

St.27 status event code: A-3-4-F10-F13-rex-PB0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20160418

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20160418

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301